I realize that Libigel as a treatment for HSDD is still around. I just think that turning things around, CV reduction-drug with HSDD-treatment as side-effect, opts for a bigger market. Especially considering LibiGel's setback in december.
Either way, there was no announcement by the company on this, was there?
And perhaps best of all: LibiGel technology is not licensed to anyone yet.....
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.